Madrigal Pharmaceuticals, Inc. (MDGL)
Largest Insider Buys in Sector
MDGL Stock Price History Chart
MDGL Stock Performance
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with …
Insider Activity of Madrigal Pharmaceuticals, Inc.
Over the last 12 months, insiders at Madrigal Pharmaceuticals, Inc. have bought $0 and sold $86.17M worth of Madrigal Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Madrigal Pharmaceuticals, Inc. have bought $77.75M and sold $29.93M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,633 shares for transaction amount of $4.71M was made by BAKER BROS. ADVISORS LP (director) on 2023‑12‑14.
List of Insider Buy and Sell Transactions, Madrigal Pharmaceuticals, Inc.
| 2024-12-03 | Sale | director | 3,600 0.0162% | $315.31 | $1.14M | -3.23% | ||
| 2024-11-25 | Sale | director | 3,400 0.0156% | $350.30 | $1.19M | -8.53% | ||
| 2024-11-21 | Sale | Chief Commercial Officer | 688 0.003% | $316.92 | $218,041 | -3.27% | ||
| 2024-11-07 | Sale | director | 5,000 0.0224% | $350.00 | $1.75M | -10.25% | ||
| 2024-11-01 | Sale | director | 5,000 0.0217% | $300.94 | $1.5M | +0.04% | ||
| 2024-09-09 | Sale | President and CEO | 6,363 0.0299% | $243.83 | $1.55M | +14.78% | ||
| 2024-06-14 | Sale | Senior VP, Chief Pharma Dev. | 1,900 0.0085% | $280.00 | $532,000 | -6.55% | ||
| 2024-06-12 | Sale | Senior VP, Chief Pharma Dev. | 2,000 0.0092% | $285.00 | $570,000 | -7.99% | ||
| 2024-05-21 | Sale | Senior VP, Chief Pharma Dev. | 1,036 0.0046% | $231.34 | $239,668 | +5.49% | ||
| 2024-05-14 | Sale | director | 22,489 0.1065% | $212.88 | $4.79M | +20.54% | ||
| 2024-04-08 | Sale | Pres., R&D, and CMO | 2,676 0.0126% | $245.99 | $658,258 | -1.87% | ||
| 2024-04-08 | Sale | director | 26,270 0.1239% | $246.19 | $6.47M | -1.87% | ||
| 2024-04-05 | Sale | Pres., R&D, and CMO | 22,228 0.1058% | $242.84 | $5.4M | +0.42% | ||
| 2024-04-05 | Sale | Pres., R&D, and CMO | 27,506 0.1312% | $243.36 | $6.69M | +0.42% | ||
| 2024-04-05 | Sale | director | 27,613 0.1317% | $243.40 | $6.72M | +0.42% | ||
| 2024-04-04 | Sale | Pres., R&D, and CMO | 13,339 0.0636% | $241.81 | $3.23M | +1.04% | ||
| 2024-04-04 | Sale | Pres., R&D, and CMO | 18,537 0.0888% | $242.91 | $4.5M | +1.04% | ||
| 2024-04-04 | Sale | director | 18,710 0.0897% | $242.96 | $4.55M | +1.04% | ||
| 2024-04-03 | Sale | Pres., R&D, and CMO | 6,839 0.0342% | $244.24 | $1.67M | -0.55% | ||
| 2024-04-03 | Sale | Pres., R&D, and CMO | 27,845 0.1399% | $245.14 | $6.83M | -0.55% |
Insider Historical Profitability
| FRIEDMAN PAUL A | director | 185735 0.8516% | $309.75 | 2 | 5 | <0.0001% |
| Levy Richard S | director | 11012 0.0505% | $309.75 | 3 | 4 | +602.61% |
| CRAVES FRED B | director | 11000 0.0504% | $309.75 | 1 | 8 | <0.0001% |
| Bahcall Safi R | President and CEO | 2053135 9.4136% | $309.75 | 12 | 0 | +16.52% |
| BAKER BROS. ADVISORS LP | director | 1793403 8.2227% | $309.75 | 9 | 0 |
Institutional Investor Ownership
| Janus Henderson | $694.53M | 12.21 | 2.6M | -10.36% | -$80.3M | 0.35 | |
| Baker Bros Advisors LP | $526.01M | 9.24 | 1.97M | 0% | +$0 | 3.78 | |
| Avoro Capital Advisors Llc | $519.24M | 9.12 | 1.94M | +2.94% | +$14.84M | 6.22 | |
| Paulson & Co. | $474M | 8.33 | 1.77M | +60.53% | +$178.72M | 32.75 | |
| The Vanguard Group | $445.64M | 7.83 | 1.67M | +5.97% | +$25.12M | 0.01 |